Herbal Medicine Around the World: How Brazil, India, the USA, and Europe Regulate It

Abstract

Herbal medicines (HM), derived from whole plants or their parts, play a crucial role in primary health care, with approximately Eighty percent of the global population relying on them. The World Health Organization (WHO) is tasked with establishing guidelines for their use, safety, and quality. Despite these standards, risks associated with self-dosing and variability in regulatory frameworks persist. Regulatory approaches differ worldwide, including Brazilian legislation through ANVISA, Indian regulations under the Drugs and Cosmetics Act, the European Medicines Agency (EMA), and the US Food and Drug Administration (FDA). Each framework enforces high standards for quality, safety, and efficacy, involving rigorous testing on human subjects. While significant strides have been made in standardization and therapeutic consistency, challenges remain. Integrating international standards aims to address these issues, focusing on reducing the risks associated with unsafe and ineffective herbal medicines for consumers. Our review tries to reflect on the various herbal regulations across Brazil, India, European Union, and USA and bring out a comparative opinion on various aspects as well as the need for harmonization of these regulations.

Keywords:
Integration; Standardization; Global; Legislation; Regulation; International

INTRODUCTION

Traditional medicines or healing comprises of using entire plants or parts of plants in wound and illness curing process. Herbal medications employ potency and medicines derived from plants to cure illnesses, enhance health, and avert diseases. These preparations, which come from plants, are used for each health need and are considered to be the oldest known system of medicine. There is a vast array of HM products and their application is extensive, and it ranges from treating depression, to colds and flu (Chegu, Nagabhushanam, 2021). According to the working definition by the World Health Organization (WHO), HM medications are complex medicinal products prepared with whole plants, plant parts or plant material blends expressing one or more active principles. Today, according to WHO, 80% of the world’s population uses herbal medicines as primary care agents, while WHO has clearly defined criteria from this evaluation ensuring wellbeing, efficacy, along with the quality of Herbal medicine (Ali et al., 2020). However, HM medications may also encompass traditional, natural, or inorganic active in some countries do not contain plant substances only. HM medication is quite an important aspect of any traditional medicine system and is particularly found in Ayurveda, Homeopathy, naturopathy among other systems. These include seeds, stems, leaves, tree bark, their roots, flowers and extracts of plants that have been used traditionally in medicinal system of humans. These natural products have been accredited with antimicrobial, antidiabetic, antifertility, anti-aging, anti-arthritic, narcotic, antidepressant, antianxiety, antispasmodic, analgesic, anti-HIV, vasodilator, hepatoprotective, and therapeutic activities for diseases like cirrhosis, asthma, acne, impotency, menopause, migraine, renal stones, chronic fatigue. Traditional medicines particularly those derived from plants have existed for roughly 4000 years and stood the test of time. Some of the herbal medications have been withdrawn from the market mainly due to toxicity concerns, while others have either been reformulated or taken together with other herbs (Chegu, Nagabhushanam, 2021).

Even though medicine is becoming more and more advanced globally and is a very successful treatment option in the modern world, people are still strongly drawn to herbal remedies. Numerous herbs have been shown to be beneficial by extensive research; some of these herbs have been included in Ayurvedic formularies for decades. This has led to numerous businesses selling Ayurvedic herbal items for both medicinal and non-medical uses. The HM goods had been released sooner. From an ethical point of view some consideration in the usage of herbal medicine include safety / efficacy of the product, the availability and conservation of the resources used, cultural sensitivity in use of these products, and fair distribution of these products. To eliminate any risks of danger it should undergo efficiencies trials after passing through the phases of clinical trials, and it should not possess any toxic substances in its composition by observing the right method of growing, harvesting as well as processing the material. The production and distribution of electricity and other necessities of life has to be controlled to some extent; and this is why, countries have formed some regulatory authorities. Sustainability concerns the preservation of biological diverse and minimization of the impacts in environments and the sustainable production and use of natural resources using nonharmful practices like ecofriendly agriculture. Some facts pertaining to cultural sensitivity include Indigenous Peoples who has rights over customs, belief and knowledge system that ought to be accorded reasonable respect and reimbursement as well as propriety over first instantiated objects (Chegu, Nagabhushanam, 2019). This meant that the issue of getting the herbal medicine to the point where they are comparatively cheap and easily available to whoever needs it while at the same time making sure that they are socially responsible in the process of making the same products. A flowchart to explain ethical considerations of herbal medicine is depicted in Figure 1.

FIGURE 1
Ethical considerations for herbal products.

Medications derived from natural sources play an important part of the primary health care systems in many of the world especially in the developing nations with age-old experience of using plant products. It is important for any government to regulate herbal compounds in order to protect the people’s health and safety in using them. This brings a quick introduction of the common and different or comparative points when it comes to control herbal medicines.in the selected countries: Brazil, India, the United States of America, and Europe. These natural products play a large part in the total healthcare systems of the world, particularly in those countries who have developed a folklore use of herbs and herbal products. The use of herbal medicine is significant and that is why regulation is important to consider for safety, quality and efficacy. This introduction gives an outline of the current and established significant legislations on herbal medicines in Brazil, India, United States and European country with their strengths or distinctive features and challenges. (Chegu, Nagabhushanam, 2019)

To the oversight of medicinal plants in Brazilian, the Brazilian Health Regulatory Agency (ANVISA) is central. The said country has diverse bio resources and has a past recorded special program on natural products especially using native knowledge. Currently, ANVISA has specific regulation regarding registration, production, and commercialization of the herbal medicines requiring that they must be safe and of quality. They include clinical trial and good manufacture practice regulations and labelling regulations among others.

Traditional systems of medicine especially the Ayurvedic and Unani system in India has a long history and they are governed under the provision of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rule 1945. This framework requires that products be approved by the Ayush Ministry and are safe for use while also trying to acknowledge traditional knowledge where applicable. The naturals are commonly used in Europe and they come under the European Medicines Agency (EMA) and are regulated by the Traditional Herbal Medicinal Products Directive. The purpose of this directive is to standardize products and guarantee their safety, efficacy, and high quality.

In US, herbal medicines are considered as over the counter/drug/Dietary Supplement under the Dietary Supplement Health and Education Act of 1994. This means there is freedom in the marketing of foods especially for the manufactures but they take the task of guaranteeing the safety of food and truthfulness of labels. The FDA regulates such products so that they can maintain safety standard and this regulates them after they have been marketed. The benefits of herbal medicine are

• Less cost;

• Durability & effectiveness

• High protection;

• Minimized side effects;

• Improved tolerance;

• Total accessibility

The drawbacks of herbal drugs include

• Inability to treat conditions that are both serious and sudden, as well as accidents.

• Self-dosing risk;

• Standardization complexity

Global Status of Herbal Medicine Regulations Worldwide

The possibilities available were the following: As a unique segment, HM’s meds are deviated recently, including doctor-recommended prescriptions, over-the-counter regular remedies, self-treatment only, dietary boosts, wellbeing sustenance, useful sustenance, and various status (Sharma, Pundarikakshudu, 2019). These terms are presented below:

Prescribed medications

Medicines that are derived from plants and need the prescription of a health care professional. These drugs are mainly monitored for their use so as to avoid the likelihood of their uses, and more so when they are used under prescription (Thakkar et al., 2020)

Over-the-Counter Medications

Medicines and devices that are made from natural plants that are available OTC. These two are considered safe for direct use over the counter without the approval of a doctor.

Self-Medication Only

Herbal medicines that are specifically allowed for use under the self-medication regime. Non-prescriptions are available without health-professional prescriptions being given and are mostly for low-intensity illnesses.

Herbal medicines as a different product category

Certain countries categorize herbal medicines separately due to their quite different properties and uses. This also applies to certain guidelines for making these products, controlling the quality, and advertising them for use in the public domain.

Dietary Supplements

Substances that are taken by mouth to improve, alter, or supplement the diet and may include vitamins, minerals, herbs, amino acids, or botanicals. Such supplements are designed to supplement the daily consumption of these foods and are therefore controlled to ensure that they are safe for consumption as well as have the right amounts of the ingredients claimed.

Health Foods

Highbrow items that are associated with certain health benefits. Because of such claims, these foods are regarded as different from ordinary foods and controlled differently because they are regarded as having qualities that make them healthy for the body.

Functional Foods

Like health foods, they are associated with certain health benefits and are sold as such and, thus, regulated as such. It is an added advantage formulated to supplement their health reputation, for instance, enhance health, or prevent diseases.

Others

This comprises products that originate from members of the plant kingdom but cannot be classified under the above-mentioned categories. They are classified by their characteristics and their intended use to enforce and monitor that they meet the safety and efficacy policies for their category.

Brazilian Regulatory System

Herbal medicine is popular in Brazil and is frequently based on both traditional methods and indigenous knowledge. Many plants, some of which are essential to Brazilian culture, are used to treat a variety of illnesses. In Brazil, the following natural remedies are frequently used:

Guaraná (Paullinia cupana), Catuaba (Erythroxylum catuaba), Boldo (Peumus boldus), Açaí (Euterpe oleracea), Andiroba (Carapa guianensis), Jaborandi (Pilocarpus microphyllus), Maracuja (Passiflora edulis) – Passion Fruit, Cinnamon (Cinnamomum verum), Sassafras (Ocotea odorifera), Echinacea (Echinacea purpurea), Cocão (Theobroma cacao), Peppermint (Mentha piperita), Cavalinha (Equisetum arvense), Chá de Boldo (Boldoa fragrans), Anamu (Petiveria alliacea).

The Brazilian Health Regulatory Agency, also known as ANVISA, is a government agency that is charged with the responsibility of the sanitary control of products and services for the purpose of protecting the health of the people. Consequently, since ANVISA is the coordinator of the National Sanitary Surveillance System, it controls many products, such as herbal medicines, to promote their safety and efficacy (Carvalho et al., 2014). ANVISA was established in 1999 by an Act 9/782/1999 with the aim of enhancing, maintaining, and promoting the health, hygiene, and safety of the products or services. The organization divides conventional herbal products and medicinal products into two groups for regulation: It is important to note that the terms used here refer to pharmacological products, specifically traditional botanical products (TBP) and herbal medicines (HM). TBP must demonstrate proof of long-term, safe, and effective use, as proven in humans over time.

Under Brazilian law, no product is allowed to be produced, packaged, labelled, marketed, or distributed to the consumer without having been registered, be it a locally produced product or an imported one. Registration of medicine is initially for a period of five decades and can be continued for equally consecutive duration of five years each. The current registration requirement for HM and THP stipulates a tight quality assurance chain, right from the ingredients used to the final product. The manufacturer has the responsibility of presenting dossiers for ANVISA registration, which include documentary reports, technical production reports, drug quality control, safety and efficacy reports, results of stability studies, and package insert models and labelling. Recommendations for renewal of HM registration are made based on determinations stated in RDC 26/2014, which in essence expects the product to maintain the properties of safety, efficacy, and quality. The manufacturer is also required to present periodic reports in pharmacovigilance that follow the set format of the Periodic Safety Update Report (PSUR). An application for registration of a Herbal drugs or for renewal of a Herbal drugs is rejected when the legal conditions as well as the requirements and procedures have not been attained as prescribed in a law, a regulation, or a statement of ANVISA (Carvalho et al., 2014). Further, if the drug was found to be injurious or there were legal conditions that the drug had to meet and failed to, the drug could also be immediately taken off the market.

The Brazilians standards were changed to permit an adequate regulation of HM according to scientific and technological progress as well as the development of access to these medicines. ANVISA has a significant responsibility to safeguard the Brazilians by regulating the herbal products for safety and efficacy, and at the same time wants to preserve the rights of the consumers to have those products.

Safety and Efficacy of Traditional Herbal Products and Herbal Medicine

Research into the safety and efficacy of herbal medications and traditional herbal items adequate benchmarks that are comparable to the standard practices in the international market, thus ensuring the safety of medicinal plants and herbal products being imported or consumed in Brazil. These include, among other things, the Standards of Medical Practice rules, which say that before anybody can do any research, the study proposals must be examined and approved by the ANVISA, followed by an additional Statement (Ekor, 2014). Supervision of natural medicines in Brazil is under the Brazilian Health Regulatory Agency known as ANVISA, and it has put measures in different measures to ensure that the herbal medicines in Brazil meet standards of efficacy and safety (Carvalho et al., 2014). ANVISA separates herbal medicines into two categories: traditional medicines TM, herbal medicines (HM) and Traditional herbal products (THP). For HM both safety and efficacy must be supported by clinical data on the product, while in the case of THP, safety and effectiveness can usually be corroborated by tradition of use or simplified registration data. The agency accepts some plants on the list of safe and efficient ones and there is a facilitated procedure of their registration; the agency also recognizes the long tradition of using medicinal plants in Brazil (Lynch, Berry, 2007).

Thus, to support claims that HM is safe and effective, companies need to provide preclinical data, clinical trials, kinetics and dynamics data. Thus, understanding the pharmacokinetic qualities of herbal medications is important in making an evaluation on their possibility of interaction with other treatment measures. Nevertheless, pharmacokinetic studies on medicinal plants are challenging to perform because of the chemical changes. In order to change the legislations of ANVISA what is necessary to have better regulatory aspects for herbal medicines in Brazil, that has published others guidelines as the Manufacturer Procedures Regulation - RDC 17/10, as well as a compilation of sources for evaluating the safety and effectiveness of herbal products (IN 05/10).

Some of the plants which are now on the streamlined list of registration involve Cynara scolymus L., Schinus terebinthifolius, and Rhamnus purshiana. All these involved in the production of a substance must meet all the parameters outlined in the list, plant organ, chemical standard / marker, plant derivative, therapeutic indications / actions, daily dose, route of administration, and restriction of use. In general, if a product is on this list, the individual is not needed to provide any further quality and effectiveness evidence (Calixto, 2000).

The popular use can also be further substantiated by ethnopharmacology or ethno-oriented use and documentation and studies, technical scientific documentation or other publications indicating twenty years of effectiveness and safety of the product. According to the law, occasional or short should be the duration of Use of the approved drug. ANVISA has been synchronizing the legal (CE) issuance to become harmonized (Calixto, 2000).

When registering a medicinal product, companies must not only establish its safety and efficacy of the product but also provide evidence that the company possesses a pharmacovigilance system capable of identifying undesirable effects or harms associated with the use of products produced by this company. RDC 04/09 offers drug surveillance standards to be applied by the governed industry.

In conclusion, the above-discussed regulatory framework of herbal products in Brazil can be seen as an attempt to provide the population with safe and effective medicines which origin can be traced back to pre-Columbian times. This prepared the ground for the harmonization of the legal standards to the international standards and put in place key guidelines on the safe and rational use of medicinal plants/human products in Brazil.

Quality Control

The Brazilian regulations of quality control of the herbal medicines entail several methods to ascertain the quality of the product. They confirm the identification of plant species and the presence or absence of contaminants in a specific habitat. Control is undertaken et all production stages: Natural medicine, herbal drugs, natural options, and herb medications are some of the terms used in acknowledging the medicines. Many of the medicinal plants are threatened by fungi that formed mycotoxins including the aflatoxins which are carcinogenic (Balekundri, Mannur, 2020). The following are some of the preventive means for this type of contamination: Regular and stable inspection and assessment of such components in pure plant materials. To diagnose a plant species, the following techniques are used: sensorial or organoleptic assessment, systemic botanical assessment (macroscopic and microscopic assessment), and phytochemical survey. In the case of herbal derivatives, the extraction techniques used and identification‖ of solvent residues are required to be documented (Calixto, 2000). The physicochemical analyses to be performed includes organoleptic characterization such as loss on drying, apparent solidity, density of liquid extracts, for dry extract the moisture loss on drying and density, for essential oils the value of refractive index and optimum angle of rotation and for fixed oils the ester and iodine values and of acidity index are carried out (Mukharjee, 2019).

Chromatographic markers analysis results: The markers’ identification using chromatographic techniques must follow quantitative and qualitative analysis of the identified markers through spectrometry. RDC 14/09 carries specific requirements coming from the quality assurance such as the reproductiveness of the herbal medicines. External quantitative control by the marker may be substituted with biological surveillance inherent in the activity of a therapeutic form. The company that applies for registration of the herbal medicine should preferably employ methodologies provided for in the pharmacopoeia recognized by ANVISA (RDC n 37/2009) for Monitoring the Quality of Herbal substances, herbal preparations and herbal medicine (Parveen et al., 2020). Otherwise, the effectiveness of the adopted methodologies needs to be confirmed. For so, the method shall put forward the factors outlined by RE 899/03 (Carvalho et al., 2011); although the guidelines were established for synthetic drugs, they are equally viable for phytopharmaceuticals. Some aspects of bioanalytical method parameters are required (Carvalho et al., 2011). After registration is given to the herbal medicine the changes in the product must immediately report the changes done to ANVISA and must provide supporting documents of the quality, safety, and efficacy of the herb. Manus must abide by the process laid down in guide for alterations and inclusions in post registered medicinal plants, RE 91/04 (Carvalho et al., 2011; Parveen et al., 2020).

The Brazilian Regulation of Plants as Medicines

The first regulation for the herbal medicines specifically in Brazil had seen it being formulated in 1967 by the late SNFMF and is referred to as Resolução 22/1967. This first of the guidelines actually proposed the fundamental parameters of registration of the herbal medicines which among other things included the right botanical identity of the plant, the quality standard, and efficient and safe proofs of the products. This has, however, over the years been amended, the now recognized one being Guideline RDC 48/2004. This guideline requires GMP certification and contains safety evaluations the same as for regular pharmaceuticals and also additional standards regarding the traditional use of the drug without unfavourable impact. Secondary legislation in the form of specific guidelines, called Resoluções Específicas (RE), enhance specific guidelines on the regulatory aspects (Carvalho et al., 2014). According to the list of reference books with scientific information on medicinal plants of RE 88/2004, there are 18 reference books that do not demand further safety and efficacy data if a plant is sufficiently referenced. RE 89/2004 gives information on 34 out of the commonly used medicinal plants specifying their names, parts used, labelling, usage, indications, doses and restrictions; in addition, it exempts other details concerning safety and efficacy for registration (Lindberg et al., 2023). The current regulation RE 90/2004 of Annex II defines guidelines for minimum requirements on preclinical toxicity testing such as the general test settings, test design and methodology for conducting Lethal Dose (LD50) tests and different kinds of toxicity tests (Calixto, 2000). The following requirements are regulated by RE 91/2004: Cancellation of registration or modification of the data registered on the herbal medicines, including posology, change of the pharmaceutical form, modification of the formulation. In the same vein, Guideline RDC 48/2004 also requires documents on the authenticity, purity, integrity and the validated qualitative and quantitative analysis on the chemical markers for quality control. Phytomedicines are considered as herbal medicines, and should be made from herbal products only, though they have to prove efficacy, safety profile, and quality comparable to an orthodox drug (Carvalho et al., 2014). Herbals cannot be registered as tea plants or parts used for making-tea preparations. To ensure the reproducibility of activity, standardized extracts and strict quality control should be presented, only the pharmaceutical industries which received the ANVISA Good Manufacturing Practices and Control certificate can register the herbal drugs. Nevertheless, the contemporary maze of medicinal plants raised probs in standardizing extracts and consistency of the therapeutic to producers who prefer to register them as cosmetics/ foods due to lenient restrictions. Furthermore, the products with herbal active are allowed to be registered as “dinamizados” (homeopathic, anthroposophical, antihomotoxic medicines) according to the Guideline 26/2007, based on the homeopathy principles and the further perspect for plant product consummation (Carvalho et al., 2014).

According to ANVISA's RDC No. 317/2019, marketing authorizations for medications may be extended for a maximum of ten years. The length of the authorization term, however, varies based on the proof that the applicant submits, taking into consideration the aim and the importance of the medication.

Challenges in Registering Herbal Treatments in Brazil

Some of the difficulties that qualify the registering of herbal medicines in Brazil include:

There being no scientific information on safety and/or efficacy of Herbal medicines becomes the main challenge while registering them (Xiong et al., 2021). This is particularly true with the herbal treatments based on plants, particularly those about which there is little information or those that have been scarcely researched on. In this case, little or no evidence suggests a high probability of such risks / benefits of the products hence leading to refusal or delay of the registration application (Carvalho et al., 2014).

Regulatory Framework

Brazil has a few and at other times, varying policies on the use of the herbal medicines. This can also lead to confusion with other associations as well as to difficulties during the registration process to allow them to fight for their cause. The legal structure is constantly changing and the regulations that need to be adhered must as well as the recommended procedures may become cumbersome for both the producers as well as the researchers.

Quality Control

In doing so, it raises the issue of quality control of herbal medicine that needs to be effectively solved. Thus, while such a system has been extensively employed in the use of herbal medicines the system has no stylized measures that provide for quality provision of the desired effects as envisaged. It primarily involves making checks on the sample of the produced item with the aim of identifying its purity, strength and presence of any impurities. However, lack of such generalities and processes as are normally followed in testing may lead to some disparities in the process and therefore the product quality-safety factor.

Pharmacovigilance

Presently, there is, however, still a relatively weak and inadequate pharmacovigilance in Brazil, especially regarding the reporting and monitoring of adverse effects of products containing medicines with herbal contributions. Pharmacovigilance can be defined as the process of monitoring the unfavourable or unintended consequences of the drug administered to patients. I would therefore wish to re-emphasise the point that this is particularly the case where the use of herbal medicines is concerned with, the fact being that it uses has inherent risk factor associated to it. Nevertheless, lack of well-defined pharmacovigilance system may create complicacy regarding problem identification and management in the area of safety.

Cost and Time

There are also certain challenges that may arise from in Brazil in the application by MVPs and the researchers in that they may take time and be expensive to accomplish the registration procedure for the use of herbal medicines. Some of the barriers that can hinder small scale producers include the registration costs and the time that may be taken in order to register so that they can be able to operate in the relevant market and in doing so be able to give a close fight to the large-scale producers in the market.

Lack of Expertise

There are many individuals who never went to school to acquire skills on utilization of herbal medicine products, and hiring from other standardized experts may be very hard, primarily as a result of access of such talents to the markets. This is because, in the absence of specialization, there may be different blunders when it relates to production and quality assurance; this would in effect impact the quality and safety of the end-product.

Bureaucratic Delays

These include; A number of demerits are associated with large abusive bureaucratic registration systems, one of them being that it creates chaos since there is convection of the registration process which in turn leads to slow registration with additional cost incurred to the producers and researches in this specific case. Registration scheduling is sequential and elaborate, therefore it takes a lot of time and everybody plays a role in between steps which are many hence prolong the process. Absence of usual interactions with people in the business likewise inability to clearly relay their plans to their subordinates may also cause bureaucratic obstacles.

Lack of Standardization

Among the problems discovered is that the herbal medicines are sometimes not produced and regulated in a standardized away which sometimes makes it hard to regulate the market of these products receiving standardized quality check. What standardisation entails is the criteria-setting of such aspects as efficiency, procedure and other procedures which should be followed when preparing these herbal drugs. This implies that while introducing the product in the market, the chances are high that the product is not producing as per the standard levels of production because the way the products are prepared and packed is also different.

Skilled workers and engineers not adequately supplied with raw materials

Easily felt herbal medicines face a number of issues and constraints when it comes to sourcing raw materials: inadequate access to raw materials, furthermore, inadequate attention to safe and sustainable ways of obtaining the materials is another problem. Sometimes perceived to be out of the control of the organisation, Raw material quality and safety have an effect on the finished product's quality and safety. It is also important to note that the irregular and unsustainable model of procurement may lead to environmental and social negative consequences.

Lack of Public Awareness

People are often unaware of the advantages and disadvantages of the use of herbal substances, which complicates efforts to ensure their safeness when used. Awareness creation through media and other forms of communication could assist in relaying information on the gains that come with use of the herbal medicines and drawbacks that are associated with them. The absence of public information on the appropriate use of herbal medicines can also have an impact on the negative effects and confirmed health problems with the use of medicines containing these herbs.

Such challenges point to the importance of a reformation of the registration process in order to create better efficiency and also the need for a raise of the emphasis on research in the field of safer and better-quality herbal medicines usable in Brazil.

The Challenges of Conducting Clinical Trials in Brazil

There are numerous factors that make trials involving herbal medicine in Brazil difficult to undertake. Unfortunately, there are very few available pharmacokinetic data for most of the identified medicinal plants, which hinders the safety and efficacy assessment. This is worse because most of the research done on the effects of herbal medicines does not help in understanding their effects in human bodies, most having been researched in test tubes (Ali et al., 2020).

Thus, regulations for herbal medicines in Brazil are still in a process of development. ANVISA has recently defined a list of priority herbal medicines, and PK studies are still not mandatory for marketing authorisation. The fact that there are not very effective regulations presents some question about the quality of, and safety of herbal products. Furthermore, there is a dire lack of a well-developed pharmacovigilance to keep track of adverse reactions of herbal medicines in the country (Aranha Brito et al., 2016).

Education of the healthcare professionals as well as the members of the community should also be imparted adequate knowledge on the safe and rational usage of the products derived from plants. Still, this is a problem in Brazil up to this present time. However, the incorporation and combination of the herbal medicines with conventional or modern medicines in the healthcare system of Brazil has been challenging due to lack of information on herb-drug interactions. (Prabhakar, Banerjee, 2021)

To compound the problem further, Brazil, being a mega diverse country in terms of medicinal plant species and rich in chemicals, poses a major challenge in terms of pharmacokinetic testing and quality assurance of herbal medicines. This proves that there is a need for further exploration of the field of herbal medicine and hope for its integration into clinical research and the whole healthcare system in Brazil. Figure 2 describes about the challenges in clinical trials of herbal drugs in Brazil.

FIGURE 2
Challenges in clinical trials of herbal drugs.

Guidelines on Regulation of Herbal Medicines in India

Herbal remedies, many of which are derived from age-old systems like Ayurveda, have a long history in India. These are a few popular herbal remedies in India.

Tulsi (Holy Basil), Neem (Azadirachta indica), Ashwagandha (Withania somnifera), Amla (Indian Gooseberry), Ginger (Zingiber officinale), Turmeric (Curcuma longa), Fenugreek (Trigonella foenum-graecum), Brahmi (Bacopa monnieri), Moringa (Moringa oleifera), Ginseng (Withania somnifera)

India has set up a comprehensive legal framework governing herbal medicines derived from its ancient tradition of Ayurveda Yoga, Unani, Siddha and Homeopathy [AYUSH]. These other traditional medicine systems are regulated and promoted under the Department of AYUSH, set up in 1995 by the Department of Health and Family Welfare. This comprehensive framework has gone through several milestones and efforts that have been made in a bid to call for safety, efficacy and quality of herbal medicines (Kumar, 2017).

Historical Development

The basics to the regulation of herbal medicines in India came with the enactment of the Drugs and Cosmetics Act in 1940. This Act was the first to give legal backing towards the production, marketing, and standardization of traditional medicines. The Act has been amended over the years to capture current developments since the industry has become complex as well as commercialized. Minor revisions were made in 1964, 1970, and 1982. National policy on traditional medicine came in 1964 and in 1970, the Central Council of Indian Medicine (CCIM) was introduced to determine educational norms of this and related medical systems (Kumar, 2017).

Some of the major regulatory bodies and frameworks include

Department of AYUSH: The organization which synthesizes the formulation, development and regulation of AYUSH systems of medicine. It interacts with numerous research councils and institutes with the aim of facilitating scientific substantiation and internationalization of traditional medicines (Verma, 2013).

Central Council of Indian Medicine (CCIM): CCIM was established in 1970 and its main objective is to formulate standards relating to education and practice in Ayurveda and Unani systems of Medicine.

Pharmacopoeia Laboratory for Indian Medicine (PLIM): Located in Ghaziabad, the presence of PLIM guarantees the quality and uniformity of herbal products. They maintain the Pharmaceutical Standard and Research Unit, the Pharmaceutical Depot, the Herbarium, and the Reference Museum. Ayurvedic Pharmacopeia of India, Unani Pharmacopeia of India. These pharmacopeia’s set guidelines in the preparation and quality of herbal products for not only their consistency but their safety as well.

Regulations and Guidelines

Drugs and Cosmetics Act, 1940: Despite this shift, this Act still stands as the foundation of regulation in herbal medicine as it was originally enacted. These commendable features are a guideline to the industry as regards manufacturing practices or policies, the kind of raw products to be used and how the final products should be labelled. A significant amendment passed in 1964 provided a definition for the term “Ayurvedic, Siddha or Unani drug” and enumerated the standard norms for manufacturing, and quality check part of the Bill (Chegu, Nagabhushanam, 2021).

Schedule TA (2008 Amendment): Brought forward in order to reduce the lack of data on raw materials used in the production of traditional medicines. This is beneficial in terms of traceability in the entire system as well as achieving the best quality in the products (Singh, Shukla, 2021).

Good Clinical Practices (GCP) Guidelines: The following guidelines are issued to maintain a standard and ethical clinical trials on traditional medicines for which the Indian Council of Medical Research (ICMR) has published these guidelines.

While Research and Development India has developed several research councils and institution which mainly deals with the scientific standardization of the traditional systems of medicine (Zhang et al., 2011). Finally, the Central Council for Research in Ayurvedic Sciences (CCRAS) was established in 1975 for the development of research in this system of Ayurvedic medicine. There are two autonomous bodies under CCIM: Central Council for Research in Unani Medicine (CCRUM) and Central Council for Research in Ayurvedic Sciences (CCRAS).

These bodies undertake rigorous research to substantiate various traditions and expand formulations and knowledge of traditional properties.

Market Regulation

In India, medicinal plants are categorized as schedule E drugs that can be prescribed for patients, non-prescription drugs and nutraceuticals. The marketing messages can be focused on references to health and nutritional benefits of the product with the prior permission from the authority. In association with the Quality Council of India, the Certification scheme for AYUSH products was brought into practice to standardize the quality and safety of AYUSH products. The certification has two levels: Standard Mark: They proposed the following for basic regulation of herbal products, which include herbal medicine products. Ayush Premium Mark: Where the imported products are to meet with higher standard measures specified internationally or by the importing country.

TKDL is the traditional knowledge digital library. The TKDL is a joint venture of the CSIR and the Department of AYUSH for extracting and compiling information from Ayurvedic literature. It helps in recording indigenous information so as to counter the vice of biopiracy and consequently enabling India to avert loss of its natural resource endowment to other entities. The TKDL database preserved more than 2,000 records of existing chemical compound patents along with other forms of intellectual property protection. Comprising of 23 lakh formulations derived from Ayurveda, Unani, and Siddha forms of medicines, it is available in various languages that can be beneficial to international patent offices (Chegu, Nagabhushanam, 2021).

Swot analysis

The strengths, weaknesses, opportunities, and threats of herbal medicines, when examined individually, provide a clearer picture of the perks and drawbacks of herbal medicines available on the market and available locally. On the positive side, the herbal medicines can be got from a rich resource of plant sources and have their basis in knowledge and cultures that have been passed on from generation to the next. The increase in the size of the market for organic products and more so the focus on matters concerning sustainability also aids the quality in the herbal extracts. Also, firms and industries spend a lot of money in research and innovation to come up with new herbal products and to further enhance the efficiency of available products. However, there are also some limitations, primarily related to: insufficient standardization, problems with infrastructure, issues related to the regulatory framework, and issues as for quality perception. Moreover, more pressing issues include the protection of intellectual property rights, requirements for globally standard and therefore simple legislation to secure safety, quality, and transparent information to reach for international markets (Parveen et al., 2020).

However, the following challenges are evident in the production of herbal medicine: That notwithstanding there are several opportunities for those producing herbal medicine. There is a clear potential and more specific opportunities that are linked to the growing trends of global natural and plant-derived products, as well as to the increasing awareness in health affairs and natural cures or remedies. The nutrient functional foods industry is also expanding and creates opportunities for use of herbal extracts in functional foods and in dietary supplements. Through the published phytochemistry profile, high throughput screening, ongoing DNA sequencing, systems biology and bioinformatics advances, the chemical basis and molecular interactions of herbal medicines can be unveiled. Last but not the least, the international cooperation can extend the development of popularizing the herbs as medicine and raise awareness Across the world.

However, there are also several threats that herbal medicine producers cannot ignore concerning the market for their products. The aspect requiring serious consideration for most players in the global herbal extract industry is the aggressive competition from the Chinese industry as it is well established. Further, issues related to IP right and preservation of geo-knowledge and bio-diversity and threats of bio-piracy remain to be a continuous issue. Another issue is that the quality perception matters, regulatory issues, contrast between oriental and occidental perception, and marketing and advertising issues that may arise because of these differences can also act as impediments to the marketing and promotion of herbal medicines internationally. Knowing these strengths, weakness, opportunities, and threats help the producers of herbal medicine for them to be in a better position in overcoming these challenges and be able to make good use of the opportunities that are available so as to have improve the acknowledgement of the herbal medicines in the world (Parveen et al., 2020).

Challenges for the Development of Herbal Formulations in India

Issues in formulation development; varying stability of herbal drug; insufficient pharmacokinetic information on herbal drugs; efficacy, bioavailability, safety, and toxicity of herbal products; quality assurance and control; lack of availability of pharmacopoeias (Rauf, Khan, 2014)

European Regulations and Guidelines

Herbal medicine has a long history and has been used for millennia in Europe. Numerous plants are used to cure and prevent a wide range of illnesses. In Europe, the following are a few of the most often used herbal remedies:

Echinacea,St. John’s Wort (Hypericum perforatum), Valerian Root (Valeriana officinalis), Lavender (Lavandula angustifolia), Peppermint (Mentha piperita), Chamomile (Matricaria chamomilla), Ginseng (Panax ginseng), Ashwagandha (Withania somnifera), Turmeric (Curcuma longa), Milk Thistle (Silybum marianum), Nettle (Urtica dioica), Yarrow (Achillea millefolium), Hawthorn (Crataegus monogyna), Rosemary (Rosmarinus officinalis).

Current rules and guidelines governing use of Herbal medicines draw their origin from Europe, and have been developed greatly in the recent past with effort being made in the provision of key directives like the Directive 2001/ EC and Directive 2004/24/EC. These directives were intended to reflect particular scenarios that firms encounter in the process of seeking marketing approval as well as in proving efficacy (Ali et al., 2020).

This regulation is special because it established the Commission for herbal medicinal products (HMPC) within the European Medicines Agency (EMA), turning the tide on the procedure at the European level. From the formation of HMPC it was intended to harmonize the registration and authorization in the EU region for herbal remedy. Thet also helped the publication of clear requirements and procedures in appraising the safety, efficacy, and quality of herbal medicinal products (Chegu, Nagabhushanam, 2021).

Based on Directive 2001/EC, Directive 2004/24/EC was framed with a clear objective of addressing issues concerning traditional herbal medicinal products. This directive could acknowledge the difficulties experienced by the traditional herbal medicines when trying to fulfil the rigorous standard for full marketing authorization especially on matters concerning efficacy (Verma, 2013). According to Directive 2004/24/EC, the HMPC is to prepare CPMP list of community herbal monographs and lists of herbal substances and preparations.

These directives gave concrete meanings to the terms herbal substances and preparations and stressed that the starting material used is natural, and many of the products are fresh. Extraction and purification treatments as well as pills and powders prepared from various parts of plants were categorized into different groups, and their preparations underwent certain standards to meet the requirements of safety and efficacy.

As for the classification of the herbal medicinal product available in Europe, they are divided and distinguished according to whether they are traditional or established medicinal products. Products classified within traditional use categories do not require new clinical trial data but are based on safety records and testimoniary evidence of safety and effectiveness; whereas products that fall under the remit of products with established traditional use require sound scientific evidence of safety and effectiveness and are usually given marketing authorization by a Member State or the EMA (Kumar, Rampp, 2024).

Thus, one of the most important concerns highlighted in the European regulations as the requirements for HMP quality assessment is their quality assurance. HMPC working documents in the form of community herbal monographs are the main documents used in the applications for both traditional use registration and the marketing authorization of the established use. These monographs are designed to set up the requirements for various herbal medicines on how they should be like in the EU market.

Significant factors that will perhaps enhance the development of herbal medicine market in Europe are; The global philosophies towards natural plant, plant health product awareness, belief that herbal products have fewer side effect compared to that of synthetic products and technological advancement in analysis of such product. Moreover, use of familiar herbs also several add to the formulation of the herbal medicine to make them popular and acceptable among consumers.

All in all, the rules and recommendations of the European public for herbal medicines, though ensuring safety, efficiency, and quality of used preparations, take into consideration the traditional, cultural aspect of such products. Codified continuously and adjusted as necessary, these regulations strive to lay down solid guidelines that could be helpful in designing, registering, and promoting herbal medicinal products in the EU region (Kumar, Rampp, 2024).

USA Regulations and Guidelines

Numerous herbal remedies are widely utilized in the United States to treat a range of medical conditions. These are a few of the more well-known ones:

Echinacea, Ginseng, Peppermint, Ginger, Turmeric, Chamomile, St. John's Wort, Lavender, Aloe Vera, Milk Thistle, Valerian Root, Ashwagandha.

Fortunately, in the USA while true herbal medicines are not completely banned outright, they are managed through bureaucracy to ensure that they are safe and as well efficient and of quality (Rojas et al., 2022). The main authority regarding to such products concerns the Food and Drug Administration, abbreviated as FDA. Here are the key regulations and guidelines governing herbal medicines in the USA (Alostad, Steinke, Schafheutle, 2018): These include the actual complete set of rules containing the guidelines on how and when to use herbal medicines and their sale in the country (Chegu, Nagabhushanam, 2021).

Dietary Supplement Health and Education Act of October 1994

DSHEA classifies herbal medicines as dietary supplements in a product naturally sourced from plant material. The U. S. congress categorizes the dietary supplement in the food segment act as goods with human consumption aspect and in this regard; they are to be ingested to complement the food. Regulation: Moreover, according to the new DSHEA act the manufacturers of the dietary supplements are privileged to put on the market their products for human consumption without seeking for approval from FDA (Zhang, 1998). However, the manufactures must be in a position to ensure that the end consumer is safe to use the product and the statements used while advertising should not be misleading as thought by the current administrator.

Current Good Manufacturing Practice or cGMP

The cGMP rules therefore make consumption of dietary supplements secure in as much as it demands the correct approach to designing, checking as well as supervising control operations. All the production operations from production of raw materials, purchase, processing, manufacturing, assembling, marketing, distributing and packaging of the final product are activities controlled by these. In the beginning, the states were inspecting and monitoring to make sure everybody was adhering to the FDA’s requirements and guidelines.

Labelling Requirements

A nutrition label should contain the following information; the name of food and the amount of it, the Supplement Facts panel, and any cautionary information. Labels can comprise one or more of the following types of claims: Health Claims: Explain how a dietary supplement can be associated with a low risk of a particular disease or health-related condition. These have to be reviewed and approved by the FDA before they can be marketed. Nutrient Content Claims: Explain the proportion of a nutrient in the product (e. g., “contains more Vitamin C”. Structure/Function Claims: Include a statement explaining that the nutrient or dietary ingredient is contained in a food to influence the structure or function of the body (e. g., “contributes to the health of the immune system”). Any of these statements must be followed by a disclaimer that the statement has not been approved by the FDA and the product has not been evaluated for its effectiveness in treating, curing or preventing this or any other disease.

New Dietary Ingredient Notification

If the dietary ingredient used as the active component of the herbal product was not sold in the United States prior to October 15, 1994, the manufacturer should inform the FDA of his intention to market the herbal product at least 75 days before introducing the same to the market. Thus, in order to initiate the notification, the manufacturer must also demonstrate that the NDI is reasonably anticipated to be safe.

Adverse Event Reporting

This information must be reported by the manufacturers, packers, and distributors in cases of serious adverse events with regards to the use of dietary supplements. They also have to keep records regarding adverse events for a period of 6 years and submit them to FDA if called for.

Enforcement Actions

Under the Food, Drug & Cosmetic Act, FDA is given the powers to carry out enforcement actions on products that are tainted, labelled wrongly or those that do not meet approved requirements. These may range from sending letters of warning, search and seizure of the product, legal restraints in the form of injunctions, criminal charges among others.

Federal Trade Commission (FTC) Regulations

This is another way the FTC polices dietary supplements so that information provided by manufacturers or sponsors does not mislead consumers. The FTC demands that to make such a claim about the product, the advertiser should be in a position to present sound and credible scientific research findings (Ali et al., 2020).

China and India account for the largest exporter in the production of herbal medicinal plants due to their bio-diversity and well-developed systems of indigenous knowledge. France and Germany are major production countries for herbal medicines in Europe and they have sophisticated industries for these medicines to meet the local and international demand (Market Research Future). In Middle East some countries include Saudi Arabia and UAE, sets from the available resources and rising population (Market Research Future) (Kumar, Rampp, 2024).

Global Herbal Medicine Market

Global market for herbal medicines has been estimated to grow from $60 billion in 2010 to $5 trillion in 2050 by Market Research. Future More and more people are using herbal medicines and the Herbal medicines markets are expanding rapidly (Agarwal et al., 2013). More and more products are being developed on the basis of Herbs Himalaya Drug Company, China, Shen Chang Pharmaceutical Company, Schwabe, Arko pharma, Madaus, Zandu Pharma, Dabur, Hamdard Laboratories, Blackmores, Tsumura, Patanjali Ayurveda, Nutraceutical International, and China Herbs Company (MRFR) are some of the well-known companies operating in this international market (Calixto, 2000).

However, several issues have been observed to plague this growth including; weak regulatory environments, poor quality controls, and lack of high quality positive evidential information related to these medicines. These issues can cause a lack of confidence and slow market penetration among key consumer groups; namely, health care practitioners. The market is also very saturated with major companies exerting competitive and dominating pressure on regional firms to constant innovation, high quality and sophisticated technologies (Market Research Future).

The possible future trends in the consumption of herbal medicines in the market are: constant improving and advancing of the product line, the combination of both traditional and natural treatment, and the incorporation of modern advanced technology in managing patients and products. Meeting the regulation issues and making improvements regarding the scholarly research will be significant for maintaining the growth in this promising market (Ghani, 2013).

Problems and Difficulties in the Development of Herbal Drugs

Formula Creation

Formula creation is the technical process of blending active pharmaceutical components with inedible particles known as carriers or diluents (Prabhakar, Banerjee, 2021).

Pure herbal formulations

Compounds created from pharmaceutical formulations contain minerals and difficulties are common in the way of proving the therapeutic value even in the context of developing formulations, involving the use of the single drug.

A polyherbal formulation (PHF) is one that has many drug components. However, the study also reveals that the bio compound present in the plant in a small amount is not enough to impart the curative value and it is also proved that single drugs are not so effective as synthesized drugs which are derived from different plant species. When combined with additional medicinal ingredients, the medicine has a more potent therapeutic effect. This is referred to as synergism. This positive drug-drug interaction is prevalent in polyherbal formulations and operates in two synergistic ways: Pharmacokinetic-Pharmacodynamic Mechanism.

The capacity of a herbal drug to improve the ADME of another drug is referred to as a pharmacokinetic synergistic plan of action, whereas pharmacodynamic methods refer to the effects of active components in polyherbal medicines on identical receptors.

It matters true that medicines like diabrid, diasulin, etc the polyherbal drugs are far more potent than the chemicals like tolbutamide gliclazide etc which are the small knapsack drug that have a very small therapeutic index. Such polyherbal drugs like diakyur were found not to have toxic effect on the animals even when administered at the highest cumulative dosage of 12800mg/kg. Therefore, the many herbal drugs are beneficial, safe, environmentally sustainable and cheap than the present modern synthetic medicines particularly those in rural areas and the inhabitants of low economic nations.

The effectiveness of polyherbal drugs cannot be questioned, but one cannot also be certain that it is safe at every point in time. Sometimes, these many Herbal medications are taken in conjunction with conventional drugs, leading to damage to organs because their safety tests were not completed and the medication was used extensively given. When it comes to the enhancement in the reproducibility of this drug in the batches after the standardization of the synthesis method, this is another problem that needs to be addressed. Variations of formulation quality from batch to batch is greatly influenced by several factors such as geographical factors such as location, climate, habitat, type of soil, method of crop growing, method of crop reaping, collection of raw materials and storage condition has a direct impact on the quality and the formulations’ reproducibility of the, drug (Prabhakar, Banerjee 2021). A flowchart describes about the steps required to be taken to develop formulations of herbal medicine based on the old traditional knowledge is sown in Figure 3.

FIGURE 3
Steps needed to produce formulations of herbal medicine based on age-old traditional knowledge.

Another major concern it the determination of heavy metals in the formulations of these products and efforts to contain or eliminate it pose a major concern. Lack of effective implementations of WHO guidelines in formulating these APIs results in a window for compromising the quality of formulations through adulteration, contamination, and poor formulation. Therefore, an efficient, economic and with low problems of dosage for simple use, there is a need of acquiring proper knowledge of proprietaries. Since this problem and challenges are closely related to the process of choosing appropriate excipients and other substances in specific amounts as per their chemical, physical and mechanical properties, it is much essential.

According to the WHO recommendation of a particular drug formulation, it must have ingredients that will defend, augment and also assure stability, bioavailability and preferably palatability of the formulation. Another reason for establishing the significance of excipients in drug development is that they provide an effective pathway for drug administration by providing a proper volume, weight, and texture. According to Ayurveda, an educed material that is an essential component of the formulation plays a proactive role in the pharmacological activity of the medicine. Artificial ingredient producers now prioritize using natural polymers because these substances exhibit non-toxic character together with economic viability and environmental-friendly properties and tissue compatibility.

Herbal product formulations include primary components, bio enhancements, backup ingredients, binders, synergistic compounds, sweeteners, colorants, and flavouring agents. These are the bio-booster ingredients that are meant to raise the bar for bioavailability, or the ability of the body to absorb the medicine. Cow urine and water, honey, shunthi and marich, and pippali are scientifically acknowledged biochemicals, whereas agar, starch, guar gums, xanthan gum, gelatin, acacia, and cellulose are well-known binders and colloidal/gelling agents. The dose generated in today's herbal drug manufacturing procedures are classified according to the dosage type, where the different dosage kinds include; solid dosage form, which includes the Gutika or churna, semi-solid dosage form, which includes the Avleha and ghrita, and finally the liquid dosage form which include asava, arista, and taila.

Safety of Herbal Drugs

It becomes suitable and vital to conduct stability tests on the herbal medicine molecule. This is done to see how the oxidation process affects humidity, heat, and radiation in natural items. These elements offer a significant threat to herbal medications, as they are prone to decay. If the combination is kept under the circumstances stated above for an extended period of time, it may become unstable or its constituents may degrade. The active components in the manufacturing process are susceptible to hydrolysis, oxidation, bacterial, or fungal attack, posing a threat to product stability on the market. The shelf life of the herbal medication composition should not fluctuate (Carvalho et al., 2014).

The FDA published some stability testing recommendations, and more appropriate analytical methods and protocols must be used to analyse the formulation's contaminants (Van Wyk, Prinsloo, 2020). The key step for both pharmacopeial validation and quantitative analysis of the identified active compounds is devoid of bias. Unlike the methodologies previously outlined, FTIR spectroscopy paired with chemometric data provides a complete metabolic fingerprint pattern of the herbal compositions.

Pharmacokinetic studies of herbal-drugs remain limited

The pharmacokinetics and pharmacodynamics of herbal drugs are poorly understood, and only a few have been reported for ADME, including curcumin, ginseng, gingko, ginger, and others. The majority of the phytocompounds are used for the first stage or second stage metabolism in in vivo studies. This has resulted in a restricted understanding of the An ADME and pharmacokinetics of the herbal medication since there is insufficient information about the active chemical adequacy and very low concentration in systemic transport, which is extremely difficult to assess. Since herbal medications have a significant impact on chronic illnesses and other conditions, it is critical to understand the pharmacokinetics in order to manage dosage and ADME to regulate desirable concentrations at the site of action, resulting in a therapeutic effect. Pharmacodynamics, Absorption, Metabolism, and Toxicological and Therapeutic View of Herbal Medicine. Measures of efficacy of herbal drug also revealed that efficacy is seen as the capacity to stimulate a beneficial response. Herbal products in previous years been known to be highly effective for some notable ailments. As most of the herbal drug lacks the research and study by the scientific groups, the efficacy of it is not reported often. This could be owing to a poor bioavailability range, low market appeal and royalties for patented production. However, as per the law in the country, these companies which sell and manufacture the herbal medicines have no legal requirement to conduct test on the effectiveness. In fact, there are no such inferences made based on existing data regarding their therapeutic use of natural products.

Role of Pharmacists in Herbal Medicine Management

Owing to increased demand of the global population on herbal medicines because of perceived safety, efficacy, cultural acceptance and cheapness, pharmacists have a crucial responsibility of supervising their use appropriately. Although effective, they should be taken with equal caution as they cause side effects and interface with conventional medicines for which supervision is compulsory. It is the role of the pharmacists to enlighten the patients on the efficacy, safety and adverse effects if any of the herbal products. This will also involve dispelling the thinking that anything that is natural is perfectly safe to be consumed. Health care providers should also discuss the patient’s intake of herbal products and products with natural ingredients with the patient to encourage the patient to disclose this information willingly. The pharmacists have to remain vigilant on possible side effects and interactions resulting from the complementary medicine and be in possession of thorough details of the possible negative effects in order to update the rest of the health care team. Caution should be taken especially when counselling clients who are pregnant or those with allergies for, they are more vulnerable to side effects in herbal products. Pharmacists should perform comprehensive evaluations of the patient’s full medication profiles and health statuses with the purpose of recognising any risks or previously witnessed concerns relating to H/CIM and CIMs (Bhowmik et al., 2009).

This involves determining the effectiveness and safety of these herbal medicines that patients are taking as well as their comparative cost. In an ideal world, pharmacies should dispense only herbal products that have been manufactures in compliance with GMP so that patients receive only the best quality products. Since pharmacists, like other members of the healthcare team, are involved in patients’ health care, they should disclose information on easily accessible herbal remedies and cooperate with the other groups. As fellow healthcare professionals, collaboration and cross-referencing on articles in relation to herbal medicines to be able to share findings in publications may help in the comprehended and management of the products. It is also closely related to the concept that to appropriately implement herbal medicines into patient care, pharmacists require information literacy and effective communication, as well as critical thinking to assess current information about such remedies. This should be accompanied by changes in the curriculum to include or elaborate on topics concerning herbal products and the role of pharmacists. Patients’ proximity should be kept close by and they should be followed up constantly with recommendations on the safety and efficacy of herbal remedies while insisting on the right medical courses that should be undertaken. Thus, by assuming those roles pharmacists can help to improve the safety, effectiveness and appropriateness of the use of herbal medicines for patients thus contributing to the advancement of patient care at large. A Comparison of various aspects of herbal medicines across Brazil, India, the USA, and Europe can be seen in Table I.

Comparison of Various Aspects of Herbal Medicines Across Brazil, India, the USA, and Europe

TABLE I
Regulatory comparison system for herbal medicines

ITEMS	BRAZIL	INDIA	US	EU
LEGISLATION	1.The Brazilian Health Surveillance Agency (ANVISA) plays a crucial role in governing the use of herbal medicines in Brazil.	The Drugs and Cosmetics Act 1940 amended 1964. The Drugs and Cosmetics Rules 2008. The Prevention of Food Adulteration Act 1954 The Bureau of Indian Standards Act 1986.	The Dietary Supplement Health and Education Act (DSHEA) of 1994) The FDA regulation 21 CFR parts 331-358 The Public Health Service Act (42 U.S.C. 262)	CD2001/83(“basic” regulation) CD 2003/63 of 25 June 2003 (Annex I, criteria) CD 2004/24 (Traditional herbal medicinal products) CD 2004/27 of 31 March 2004 (HMPC)
COMMITTEE	1. National Committee of Medicinal Plants and Herbal Medicines: This committee is responsible for supporting the harmonization of the Brazilian market and ensuring the safe and effective use of herbal medicines.	1.Research Councils (ICMR and CSIR)	1.Center for Drug Evaluation and Research (CDER). 2. National Centre for Com-plementary and Alternative Medicine	Central European Authority with specified tasks. Committees and Working Parties Herbal Medicinal Products Committee – HMPC Monographs and List Working Party - MLWP
	2. Ministry of Health: The Ministry of Health plays a crucial role in regulating herbal medicines in Brazil. It has implemented financial incentives to encourage research on medicinal plants, leading to an increase in research programs.	2. Department of AYUSH
	3. Brazilian Health Surveillance Agency (ANVISA): ANVISA is the primary regulatory agency responsible for overseeing herbal medicines in Brazil. It has been modifying Brazil's legislation to align with international standards and ensure safe access to herbal products.
	4. National Policy on Medicinal Plants and Herbal Medicine: This policy aims to encourage research in medicinal plants through financial incentive pro-grams organized by the Ministry of Health and other governmental agencies.
REGISTRATION PATHWAYS	1.Regulatory pathway for herbal medicines overseen by ANVI-SA, with requirements for proof of safety, efficacy and quality.	1.Similar as medicines	1.Botanical drug with Federal Food, Drug and Cosmetic Act.	The HMPC lacks stan-dardized reference stra-tegy materials for each treatment item, including HM's. Nonetheless, Member States may concern normal HMs items to the HMPC in two exceptional circumstances: Adequacy of evidence of long-term use-The HMPC evaluates if evidence of long-term use of a comparable item is appropriate (PDF symbol Article 16c (1)(c) of Di-rective 2001/83/EC). Conventional use under 15 years - HMPC considers if an improved-on enlistment is possible if the product has been used in the EU for less than 15 years (PDF symbol Article 16c (4) of Directive 2001/83/EC). These references to the HMPC result in an assessment, but not a limiting European Union approach Now and again, Article 16c (4) references may likewise prompt a monograph which Mem-ber States will consider. On occasion, referen-ces to Article 16c (4) may prompt a monograph that Member States will consider.
REGULATORY AUTHORITY	1.The regulatory authority for herbal medicines regulation in Brazil is the Brazilian Health Surveillance Agency (ANVI-SA).	1.Ministry of AYUSH and CDSCO	1.Food and Drug Administration	1.European Union

CONCLUSION

Herbal medicines are integral to preventive, curative, and palliative health care systems worldwide. Despite their significance, regulatory frameworks vary widely to address concerns about efficacy, toxicity, and product quality. The production of herbal medicines has raised substantial issues regarding both human health and environmental impact. In response, Brazil, India, the European Union, and the United States have established stringent regulatory standards. Nonetheless, challenges persist, including the need for standardized therapeutic practices and the assurance of reliable outcomes. Striving for international regulatory coherence while continually advancing and refining these frameworks is crucial to ensuring that herbal medicines are safe, effective, and of the highest quality for consumers globally.

ACKNOWLEDGEMENT

The authors are very thankful to Shri Vishnu College of Pharmacy, Bhimavaram for providing the necessary facilities.

ABBREVIATIONS

• HM  Herbal Medicines
• WHO  World Health Organization
• HIV  Human Immuno Deficiency Virus
• ANVISA  Agencia Nacional De Vigilancia Sanitaria
• FDA  Food and Drug Administration
• OTC  Over the Counter
• TBP  Traditional Botanical Product
• THP  Traditional Herbal Product
• RDC  Regional Distribution Centre
• PSUR  Periodic Safety Update Report
• RE  Resolucoes Especificas
• MVPS  Minimum Viable Product
• PK  Pharmacokinetics
• AYUSH  Ayurveda, Yoga, Naturopathy, Unani, Siddha and Homeopathy
• CCIM  Central Council of Indian Medicine
• PLIM  Pharmacopoeia Laboratory for Indian Medicine
• ICMR  Indian Council of Medical Research
• GCP  Good Clinical Practice
• CCRUM  Central Council for Research in Unani Medicine
• CCRAS  Central Council for Research of Ayruvedic Medicine
• CSIR  Council of Scientific & Industrial Research
• TKDL  Traditional Knowledge Digital Library
• HMPC  Committee on Herbal Medicine Product
• CPMP  Committee for Proprietary Medicinal Product
• NDI  Non-Destructive Inspection
• FTC  Federal Trade Commission
• PHF  Poly Herbal Formulation
• ADME  Absorption, Distribution, Metabolism and Excretion
• API’S  Active Pharmaceutical Ingredient
• CDER  Centre for Drug Evaluation and Research
• CDSCO  Central Drug Standard Control Organization

• INSTITUTIONAL REVIEW BOARD STATEMENT
  Not applicable.
• INFORMED CONSENT STATEMENT
  Not applicable.
• FUNDING
  Nil

DATA AVAILABILITY STATEMENT

All data is available within the article or its supplementary materials

REFERENCES

• Agarwal P, Alok S, Fatima A, Verma A. Current scenario of herbal technology worldwide: An overview. Int J Pharm Sci Res. 2013;4(11):4105-4117.
• Ali F, Khasimbi S, Sharma K, Trivedi M, Ali A, Ahmad J. Regulatory perspectives of Herbal Medicinal Products. In: Bioactive Phytochemicals: Drug Discovery to Product Development. BENTHAM SCIENCE PUBLISHERS; 2020. p. 158–75.
• Alostad AH, Steinke DT, Schafheutle EI. International comparison of five herbal medicine registration systems to inform regulation development: United Kingdom, Germany, United States of America, United Arab Emirates and Kingdom of Bahrain. Pharmaceut Med [Internet]. 2018;32(1):39–49. Available from: http://dx.doi.org/10.1007/s40290-018-0223-0
  » http://dx.doi.org/10.1007/s40290-018-0223-0
• Aranha Brito MC, Godinho JWLDS, Ferreira TTD, Araújo Luz TRS, Costa Leite JA, Moraes DFC, et al. Trade and quality control of medicinal plants in Brazil. Int J Pharm Pharm Sci [Internet]. 2016;8(10):32. Available from: http://dx.doi.org/10.22159/ijpps.2016v8i10.12983
  » http://dx.doi.org/10.22159/ijpps.2016v8i10.12983
• Balekundri A, Mannur V. Quality control of the traditional herbs and herbal products: a review. Futur J Pharm Sci [Internet]. 2020;6(1). Available from: http://dx.doi.org/10.1186/s43094-020-00091-5
  » http://dx.doi.org/10.1186/s43094-020-00091-5
• Bhowmik D, Kumat KPS, Tripathi P, Chiranjib B. Traditional Herbal Medicines: An Overview. Appl Sci Res. 2009;1(2):165-177.
• Calixto JB. Efficacy, safety, quality control, marketing and regulatory guidelines for herbal medicines (phytotherapeutic agents). Braz J Med Biol Res [Internet]. 2000;33(2):179–89. Available from: http://dx.doi.org/10.1590/s0100-879x2000000200004
  » http://dx.doi.org/10.1590/s0100-879x2000000200004
• Carvalho ACB, Perfeito JPS, Costa e Silva LV, Ramalho LS, Marques RF de O, Silveira D. Regulation of herbal medicines in Brazil: advances and perspectives. Braz J Pharm Sci [Internet]. 2011;47(3):467–73. Available from: http://dx.doi.org/10.1590/s1984-82502011000300004
  » http://dx.doi.org/10.1590/s1984-82502011000300004
• Carvalho ACB, Ramalho LS, de Oliveira Marques RF de O, Perfeito JPS. Regulation of herbal medicines in Brazil. J Ethnopharmacol [Internet]. 2014; 158:503–6. Available from: http://dx.doi.org/10.1016/j.jep.2014.08.019
  » http://dx.doi.org/10.1016/j.jep.2014.08.019
• Chegu S, Nagabhushanam MV. A comprehensive study on Regulation of herbal drugs in India, US and European union. Int J Drug Regul Aff [Internet]. 2021;9(1):78–86. Available from: http://dx.doi.org/10.22270/ijdra.v9i1.458
  » http://dx.doi.org/10.22270/ijdra.v9i1.458
• Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol. 2014 Jan 10;4:177. doi: 10.3389/fphar.2013.00177 PMID: 24454289; PMCID: PMC3887317.
  » 10.3389/fphar.2013.00177
• Ghani A. Herbal Medicines: Present Status, Future Prospects. 2013. Available from: https://www.pharmabiz.com/NewsDetails.aspx?aid=78355&sid=21
  » https://www.pharmabiz.com/NewsDetails.aspx?aid=78355&sid=21
• Kumar S, Rampp T. Concept of fasting therapy in the traditional Indian medicine of Ayurveda. Curr Tradit Med [Internet]. 2024;10(4). Available from: http://dx.doi.org/10.2174/2215083810666230505104229
  » http://dx.doi.org/10.2174/2215083810666230505104229
• Kumar V. Herbal medicines: Overview on regulations in India and South Africa. World J Pharm Res [Internet]. 2017;690–8. Available from: http://dx.doi.org/10.20959/wjpr20178-9091
  » http://dx.doi.org/10.20959/wjpr20178-9091
• Lindberg K, Martvall A, Bastos Lima MG, Franca CSS. Herbal medicine promotion for a restorative bioeconomy in tropical forests: A reality check on the Brazilian Amazon. For Policy Econ [Internet]. 2023;155(103058):103058. Available from: http://dx.doi.org/10.1016/j.forpol.2023.103058
  » http://dx.doi.org/10.1016/j.forpol.2023.103058
• Lynch N, Berry D. Differences in perceived risks and benefits of herbal, over-the-counter conventional, and prescribed conventional, medicines, and the implications of this for the safe and effective use of herbal products. Complement Ther Med [Internet]. 2007;15(2):84–91. Available from: http://dx.doi.org/10.1016/j.ctim.2006.06.007
  » http://dx.doi.org/10.1016/j.ctim.2006.06.007
• Mukharjee PK. Quality control and evaluation of herbal drugs. Elsevier Inc; 2019.
• Parveen B, Parveen A, Parveen R, AHMad S, AHMad M, Iqbal M. Challenges and opportunities for traditional herbal medicine today with special reference to its status in India. Ann Phytomed [Internet]. 2020;9(2). Available from: http://dx.doi.org/10.21276/ap.2020.9.2.8
  » http://dx.doi.org/10.21276/ap.2020.9.2.8
• Prabhakar P, Banerjee M. Technical Problems, Regulatory and Market Challenges in Bringing Herbal Drug into Mainstream of Modern Medicinal Practices. Res J Biotechnol. 2021.16. 212-222.
• Rauf A, Khan H. Medicinal Plants: Economic Perspective and Recent Developments. World Applied Sci J. 2014, 31.1925-1929. doi: 10.5829/idosi.wasj.2014.31.11.14494
  » 10.5829/idosi.wasj.2014.31.11.14494
• Rojas P, Jung-Cook H, Ruiz-Sánchez E, Rojas-Tomé IS, Rojas C, López-Ramírez AM, et al. Historical aspects of herbal use and comparison of current regulations of herbal products between Mexico, Canada and the United States of America. Int J Environ Res Public Health [Internet]. 2022;19(23):15690. Available from: http://dx.doi.org/10.3390/ijerph192315690
  » http://dx.doi.org/10.3390/ijerph192315690
• Sharma AK, Pundarikakshudu K. Regulatory aspects of traditional Indian medicines (TIM) in India and in international purview. J AOAC Int [Internet]. 2019;102(4):993–1002. Available from: http://dx.doi.org/10.5740/jaoacint.18-0379
  » http://dx.doi.org/10.5740/jaoacint.18-0379
• Singh S, Shukla VK. Current regulations for herbal medicines in India. Int J Drug Regul Aff [Internet]. 2021;9(2):30–4. Available from: http://dx.doi.org/10.22270/ijdra.v9i2.466
  » http://dx.doi.org/10.22270/ijdra.v9i2.466
• Thakkar S, Anklam E, Xu A, Ulberth F, Li J, Li B, et al. Regulatory landscape of dietary supplements and herbal medicines from a global perspective. Regul Toxicol Pharmacol [Internet]. 2020;114(104647):104647. Available from: http://dx.doi.org/10.1016/j.yrtph.2020.104647
  » http://dx.doi.org/10.1016/j.yrtph.2020.104647
• Van Wyk AS, Prinsloo G. Health, safety and quality concerns of plant-based traditional medicines and herbal remedies. S Afr J Bot [Internet]. 2020;133:54–62. Available from: http://dx.doi.org/10.1016/j.sajb.2020.06.031
  » http://dx.doi.org/10.1016/j.sajb.2020.06.031
• Verma N. 1. Herbal Medicines: Regulation and Practice in Europe, United States and India. Int J Herb Med. 2013;1(4):1–5.
• Xiong Y, Gao M, van Duijn B, Choi H, van Horssen F, Wang M. International policies and challenges on the legalization of traditional medicine/herbal medicines in the fight against COVID-19. Pharmacol Res [Internet]. 2021;166(105472):105472. Available from: http://dx.doi.org/10.1016/j.phrs.2021.105472
  » http://dx.doi.org/10.1016/j.phrs.2021.105472
• Zhang J, Wider B, Shang H, Li X, Ernst E. Quality of herbal medicines: challenges and solutions. Complement Ther Med [Internet]. 2012;20(1–2):100–6. Available from: http://dx.doi.org/10.1016/j.ctim.2011.09.004
  » http://dx.doi.org/10.1016/j.ctim.2011.09.004
• Zhang X. Regulatory Situation of Herbal Medicines a World-Wide Review. who/TRM/1998. 98:1–45.

Edited by

• Associated Editor:
  Associate Editor: Camila Manoel Crnkovic

Publication Dates

• Publication in this collection
  01 June 2026
• Date of issue
  2026

History

• Received
  13 Sept 2024
• Accepted
  12 Feb 2025